The company published positive peer-reviewed clinical evidence supporting its ReWalk exoskeleton with statistically significant improvements in patient outcomes (performance, satisfaction, pain reduction). Additionally, ReWalk sales grew 13% year-over-year to $2.5 million in Q2 2026, total revenue increased 16% to $6.6 million, and the company is expanding distribution partnerships (Ottobock Care pilot) and securing Medicare coverage, indicating strong commercial momentum and clinical validation.
The appointment of an experienced Chief Medical Officer with 30 years of expertise signals organizational strengthening and strategic advancement. The promotion reflects confidence in leadership and supports the company's expansion into new therapeutic areas, including its biomedical pipeline. The recent successful Oratech acquisition and $10 million financing further support positive momentum.
Shareholder approval of strategic partnership provides up to $47 million in capital, diversifies business into biotechnology, maintains focus on profitable core business, and positions company for long-term growth with reduced financial risk through Oramed's funding of clinical development.
The company successfully regained compliance with Nasdaq listing requirements after previously falling below the minimum bid price threshold. This demonstrates recovery and continued market presence, which is a positive development for shareholders and the company's operational status.
Also mentions LFWD
Articles that tag LFWD but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
